Pankit Vachhani, MD, is an associate professor of medicine at the University of Alabama at Birmingham.
A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering a practical strategy that does not compromise efficacy.
A post-hoc analysis of the phase 3b JUMP trial found that ruxolitinib plus anemia supportive care maintained efficacy and reduced transfusion needs in patients with myelofibrosis.
A post-hoc analysis of the phase 3b JUMP trial assessed outcomes in patients with myelofibrosis and baseline anemia who were treated with ruxolitinib alongside anemia-supportive therapies, according to Pankit Vachhani, MD.
